Literature DB >> 8672739

Influence of clinicopathological variables on CYP protein expression in human liver.

J George1, K Byth, G C Farrell.   

Abstract

Drug metabolism is usually impaired in malnourished patients with decompensated cirrhosis, but the separate influence of clinicopathological variables, including nutritional status, on the expression of hepatic cytochrome P450 proteins has not been well characterized. We determined the hepatic content of CYP1A2, CYP2C8/10, CYP2E1 and CYP3A proteins in 71 subjects, 21 with histologically normal livers and 50 with chronic liver disease, and then tested for potential relationships between patient variables and individual CYP proteins by multivariate linear regression analysis. Variables analysed included nutritional status (determined by experienced clinicians), serum albumin and bilirubin concentrations, prothrombin time, the grade of ascites and hepatic encephalopathy, and the Child-Pugh score. Impaired nutrition and cachexia were associated with reductions of CYP2C8/10 levels of approximately 19 and 39%, respectively, relative to cases in which nutrition was replete. Similarly, CYP2E1 protein was reduced by approximately 13 and 26%, according to the apparent severity of nutritional impairment. In contrast, nutritional status did not contribute to variability in expression of CYP1A2 or CYP3A proteins. Of the clinicopathological variables analysed, only serum bilirubin was shown to have an independent influence on CYP protein content. Thus, elevated serum bilirubin concentrations were associated with significant declines in the contents of CYP1A2 and CYP2C8/10 but not CYP3A or CYP2E1. The mechanisms for the effects of nutritional status and serum bilirubin concentration on the levels of CYP proteins are unclear, but could be mediated by factors such as cytokines, dietary composition and alterations in the level of serum bile acids. Knowledge of the influence of clinicopathological factors and nutritional status on CYP expression should lead to more rational drug prescribing in patients with hepatic disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8672739     DOI: 10.1111/j.1440-1746.1996.tb00007.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Modification of CYP2E1 and CYP3A4 activities in haemoglobin E-beta thalassemia patients.

Authors:  Nuntiya Somparn; Upa Kukongviriyapan; Wichittra Tassaneeyakul; Arunee Jetsrisuparb; Veerapol Kukongviriyapan
Journal:  Eur J Clin Pharmacol       Date:  2006-11-21       Impact factor: 2.953

2.  Asenapine pharmacokinetics in hepatic and renal impairment.

Authors:  Pierre Peeters; Howard Bockbrader; Edwin Spaans; Peter Dogterom; Kenneth Lasseter; Thomas Marbury; Gordon L Gibson; Rik de Greef
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

3.  Influence of cirrhosis on lamotrigine pharmacokinetics.

Authors:  P Marcellin; F de Bony; C Garret; C Altman; V Boige; C Castelnau; P Laurent-Puig; J C Trinchet; P Rolan; C Chen; J P Mamet; R Bidault
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

4.  How to calculate the dose of chemotherapy.

Authors:  Howard Gurney
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

5.  Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients.

Authors:  Kristine Hole; Petra L Heiberg; Caroline Gjestad; Lise L Mehus; Øyvind Rø; Espen Molden
Journal:  Pharmacol Res Perspect       Date:  2018-09-11

Review 6.  Pharmacokinetics of drugs in cachectic patients: a systematic review.

Authors:  Katja Trobec; Mojca Kerec Kos; Stephan von Haehling; Jochen Springer; Stefan D Anker; Mitja Lainscak
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.